Alagebrium
- Generic Name
- Alagebrium
- Drug Type
- Small Molecule
- Chemical Formula
- C13H14NOS
- CAS Number
- 393121-34-1
- Unique Ingredient Identifier
- DGH49JXB1F
- Background
Alagebrium has been investigated for the treatment and prevention of Aging, Heart Failure, Physical Activity, Diabetic Nephropathy, and Cardiovascular Disease, among others.
A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
- First Posted Date
- 2013-08-01
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Cardiovascular Clinical Studies
- Target Recruit Count
- 134
- Registration Number
- NCT01913301
The Effect of Exercise and Alagebrium on the Diastolic Function of the Heart
Phase 2
Completed
- Conditions
- Ventricular Function
- Interventions
- Behavioral: Aerobic Exercise TrainingBehavioral: Tai Chi and/or Yoga Training
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 62
- Registration Number
- NCT01014572
- Locations
- 🇺🇸
The Institute for Exercise and Environmental Medicine, Dallas, Texas, United States
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 160
- Registration Number
- NCT00662116
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
Phase 2
Terminated
- Conditions
- Diabetes Mellitus, Type 1Diabetic Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00557518
- Locations
- 🇦🇺
Dept. of Clinical and Biomedical Science Myers House, Geelong, Victoria, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Austin Health, Heidelburg, Victoria, Australia
Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)
Phase 2
Terminated
- Conditions
- Hypertension
- First Posted Date
- 2004-08-12
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 392
- Registration Number
- NCT00089713
- Locations
- 🇺🇸
Alteon Inc., Parsippany, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath